** Shares of therapy developer Soligenix SNGX.O rise 47.5% to $4.08 premarket

** Company says FDA has granted "orphan drug" tag for its treatment of Behcet's disease after the review of mid-stage study data

** Co is testing dusquetide, the active ingredient in SGX945, in patients with mild to moderate Behcet's disease

** Behcet's disease is a rare inflammatory disorder that can affect various parts of the body, most notably causing painful sores in the mouth and genitals, along with eye inflammation

** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.

** Up to last close, stock was up 3.2% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))